NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

Ernexa Therapeutics Inc. (ERNAW) Stock Analysis

Ernexa Therapeutics Inc. (ERNAW) is a stock listed on NASDAQ and quoted in US Dollar.

ERNAW

$0.06

+$0.01 (+25.27%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on Ernexa Therapeutics Inc. (ERNA) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View ERNA →

Price History

Hover for the daily close. The dotted line marks the period open.

ERNAW Key Statistics

As of Sep 4, 2026
Trading
Open
$0.05
Previous Close
$0.05
Day's Range
0.04–0.06
52-Week Range
0.04–0.06
Volume
18.11K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.62

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Recent News

News provided by third-party sources. Not financial advice.

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Visit website →